CD274 and Merkel cell skin cancer: Within this context, the PD-1/PD-L1 immune checkpoint inhibitors Avelumab, Pembrolizumab and Nivolumab have shown promising results in advanced stage MCC, supporting a “Standard of Care” use of these agents for metastatic MCC [1].